Amanda Cespedes

I am quite new to the medical device compliance domain. Sometimes that makes me feel ignorant; at the same time it helps to neutrally look at ways to support QA RA teams in their productivity. Most QA/RA teams work across several systems: document repositories, eQMS, ticketing tools, supplier portals, and shared drives. Reviews become slow when evidence and actions cannot move cleanly between them. That would personally drive me nuts (hence I'd never be a good QA RA :)). Our roadmap has three themes we want to build with power users. * Integrations that reduce manual handoffs Examples include exporting outputs in formats that can be attached to eQMS records, linking findings to CAPA and change controls, and supporting workflows that consultants can reuse across clients. * Review outputs that are audit-friendly Clause-level status, evidence links to document name and page, reviewer notes, and a traceable record that is easy to share internally. * More frameworks across industries We started with medical device focused needs because that is where we felt the pain directly. Next, we are expanding into life sciences and pharma workflows. After that, we plan to support sustainability, IT, shipping, and other domains where clause-based evidence discovery is still manual and time-consuming. We already have a working gap analysis product with active users. The focus now is building the right roadmap and workflow details with a small set of founding customers. If you want to be part of that group in Q1, reach out. We are prioritising QA/RA leads and consultants who can pressure-test the workflow with real documentation sets.

17

New FDA Draft Guidance on QMSR – Are You Ready for What’s Coming?   The FDA has just released a draft guidance outlining the Quality Management System (QMS) information that must be included in PMA and HDE submissions starting February 2, 2026, when the new Quality Management System Regulation (QMSR) takes effect.   This marks a significant shift from the previous QSR requirements.   What’s changing?   ✅ Facility Diagrams Manufacturers must submit detailed diagrams showing the physical layout of manufacturing spaces to demonstrate proper segregation of materials and processes.   ✅ Internal and Supplier Audit Access FDA will now expect visibility into internal audits, supplier evaluations, and management review outputs—documents that previously weren’t subject to FDA inspection.   ✅ Stronger Focus on Risk Management Risk-based thinking is now embedded in nearly every element of the QMS—from design control to CAPA, supplier management, and beyond.   ✅ Traceability Matrix Submissions should include documentation that clearly traces design inputs to outputs, supporting transparency and verification.   ✅ Software and Equipment Validation Manufacturers must validate software and measurement systems used in quality-related processes—based on the associated risk level.   And what about 510(k) submissions?   While this guidance specifically addresses PMA and HDE, it’s reasonable to assume that similar expectations will soon apply to 510(k) submissions as well. Why?   ✔ QMSR will apply to all device manufacturers after February 2026 ✔ FDA inspections will follow the same QMSR expectations, regardless of submission type ✔ The industry is moving toward harmonized global standards (ISO 13485:2016)   Don’t wait until QMSR becomes mandatory At MEDAGENT, we help manufacturers prepare early—through gap assessments, audit readiness, QMS updates and Premarket Submission reviews that meet both FDA and ISO standards.   Want to know how your QMS measures up? Let’s talk.   #FDA #QMSR #MedicalDevices #RegulatoryCompliance #510k #PMA #QualitySystem #ISO13485 #RiskManagement #MEDAGENT #QSRtoQMSR

3

FDA QMSR Update: The Countdown to 2026 Has Begun On February 2, 2026, the FDA’s new Quality Management System Regulation (QMSR) will officially take effect — marking one of the most significant U.S. regulatory transitions in decades. This change brings FDA expectations into full alignment with ISO 13485:2016, and for manufacturers who haven’t begun preparing, the window of time is closing quickly. What QMSR Means for Manufacturers To support the industry through this transition, at Arazy Group we assist MedTech companies worldwide with: -QMSR Gap Analysis A structured review comparing your current QMS with QMSR requirements to identify missing elements and improvement needs. -QMS Upgrade & Transition Planning Hands-on support to develop and implement the updates needed across processes, documentation, and controls to achieve full compliance with QMSR and ISO 13485:2016. -QMSR Audit Support Independent validation to ensure your transition is complete and all gaps are closed. If your organization hasn’t started the transition yet, now is the right time to begin to avoid compliance risks and operational delays. At Arazy Group, we guide manufacturers through every step of this shift—ensuring a smooth, timely, and fully compliant transition. Visit our website or contact our team to learn how we can support your QMSR transition with confidence: https://hubs.ly/Q03WmN0Z0 #FDA #QMSR #QualityManagement #ISO13485 #RegulatoryAffairs #MedicalDevices #RegulatoryUpdates #Compliance #MedTech #ArazyGroup

12

#6 The Heart of QMS: Is Your CAPA System Proactive or Just "Putting Out Fires"? In the fast-paced MedTech world, it’s easy to get trapped in a "reactive loop"—fixing errors as they happen just to keep the production line moving. In the latest episode of The Elendi Files, Teddy Lam (General Manager of ElendiLabs) sits down with Jan Ulrich from Essence Consulting Services. With over 27 years of experience, Jan is the person companies call for "rescue projects" when their Quality Management System (QMS) is overwhelmed. Key highlights from this deep dive into CAPA include: ❤️ The Heart of QMS: CAPA (Corrective and Preventive Action) isn't just a regulatory box to check; it’s the structural foundation that ensures errors don't recur. Jan breaks down the "Proactive" vs. "Reactive" loops that define a healthy organization. Correction vs. Corrective Action: A Correction is a one-time fix for an isolated defect. A Corrective Action requires a deep dive into the root cause to ensure the error never happens again. Mixing these up can clog your system with unnecessary paperwork. Global Alignment: A major shift occurred in February 2026—the FDA has officially placed ISO 13485 at the heart of its law. Understanding Chapters 8.5.2 and 8.5.3 is now more critical than ever for global market access. Stripping Away the Layers: Why do errors keep happening? Jan advocates for the "5 Whys" and Fishbone (Ishikawa) diagrams to get past the symptoms and find the true root cause. The Swiss Rescue Mission: Hear how a manufacturer facing a massive backlog of non-conformities cleared their slate in just weeks by implementing a structured CAPA Review Board (CRB) and empowering subject matter experts. The CAPA Workflow at a Glance: Initiation & Verification: Don't double-up on open issues. Root Cause Analysis: Use the "5 Whys" to dig deep. Action Plan: Define clear steps for Correction, Corrective, or Preventive actions. Verification of Effectiveness (VoE): Prove the problem is actually solved before closing the loop. Don’t wait for a "rescue mission" to fix your quality processes. A robust CAPA system is a long-term investment that pays off in smoother audits and better products. For more insights and to connect with vetted specialists like Essence Consulting Services, visit elendilabs.com or find us on LinkedIn. Want to be on the show? If your company is interested in sharing industry expertise, please reach out to Teddy Lam. Need Quality or Regulatory Support? Feel free to get in touch with Teddy Lam Follow LinkedIn: Teddy Lam 📖 Read the Feature Article here: https://lnkd.in/g2ZxRq8W 🎧 Listen to the Podcast episode: https://lnkd.in/gqBMTQ-J #MedicalDevices #QualityAssurance #ISO13485 #CAPA #MedTech #FDA #RegulatoryCompliance #LifeSciences #QMS #HealthcareInnovation #ElendiLabs #EssenceConsulting

2

Regulatory Clarification! Exo Advantage distributes all 510(K) cleared devices! If you understand the regulations, you'll be able to make the best choice for your practice! It's important to realize you can use a device off-label, but you cannot make your own device. The device you use off-label must have an in vivo 510(K) clearance. It's important to note that the FDA does not regulate the practice of medicine. Clinicians are free to use a product off-label as long as certain responsibilities are met. It is also important to know that ALL PRP devices are used off-label. “The PRP can then be mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.” No one is mixing with bone chips! Per FDA, when the intent is the practice of medicine, clinicians "have the responsibility to be well informed about the product, to base its use on firm scientific rationale and on sound medical evidence, and to maintain records of the product's use and effects," however, they do not require submission of an IND or IDE or oversight from an institutional review board (IRB). Several cell-based studies have demonstrated positive effects of plasma preparations on human tendon, muscle, and bone tissue, with higher dose preparations being more efficacious. In summary, 1) all PRP devices are used off-label, 2) the literature supports high dose, and 3) following FDA guidelines for off-label use suggests choosing the highest dose option based on the research. Therefore, Exo seems the conservative FDA-compliant choice. Under FDA guidance, if you believe the literature somehow supports a low-dose PRP protocol, then choose a different option. We distribute a bag that is a stand-alone 510(K) cleared class 2 device for holding a fluid mixture to be administered to a patient.  We sell a centrifuge that is an FDA class 1 device cleared for centrifuging material, including blood, to make a cell concentrate. To take that centrifuge product and deliver it in vivo means the vessel should have a class 2 in vivo clearance. Exo Advantage checks both boxes! Distributors and device manufacturers often put multiple products that have separate 510(K) stand-alone clearances in a box. This is just common sense; open a box shipped to a hospital from Medtronic, and it likely has more than one item in it that has different stand-alone clearances. When you truly take the time to understand the regulations and research, the safest choice from a regulatory perspective is to select the protocol that utilizes a Class 2 510(K) cleared in vivo device, off-label, that provides the highest dose. I hope this post puts an end to any misinformation that has been posted previously. We look forward to supporting our customers with FDA-cleared products that have in vivo indications.

20

3 Comments

One of the areas FDA reviewers examine most closely during a submission review is how well these five parts of the quality system hold together. We broke them down here.

7

2 Comments

The device team thought they were following the playbook. Pick a predicate, show substantial equivalence, get clearance. But the FDA just rewrote the playbook. With its draft 510(k) guidance, the agency is sending a blunt message: yesterday’s shortcuts won’t cut it anymore. Here’s what’s changing: Predicates must be modern. No more leaning on decades-old devices that bypass today’s biocompatibility or cybersecurity standards. Clinical data is no longer rare. If bench tests can’t capture real-world risks, expect to run trials. Orthopedics and diagnostics are already seeing this shift. Implants face the highest bar. Long-term fatigue, degradation, and patient labeling are now baseline expectations. For sponsors, this means front-loading evidence. Instead of waiting for an AI request to derail a “90-day” review into a year-long saga, you’ll know the rules up front. For patients, it’s even bigger: “substantial equivalence” will no longer mean “good enough by 1990’s standards.” It will mean safe and effective by today’s. The 510(k) program is evolving from a backward-looking comparison into a forward-looking validation. And that shift will transform how devices come to market. Do you think these guidances strike the right balance between speed and safety—or will they slow down innovation too much? Full article here: https://lnkd.in/dp5Tq3Gy #FDA #MedTech #MedicalDevices #ClinicalTrials #RegulatoryAffairs

1

Audit coming up? Is Your Team Ready? For medical device companies, audits aren’t just a regulatory checkpoint, they’re a moment of truth. Whether it’s an FDA inspection, ISO 13485 surveillance, or MDR notified body audit, the stakes are high. And yet, many teams wait until the last minute to prepare. That’s where Mock Audits for readiness comes in. I work with MedTech businesses to simulate real-world audit conditions, identify gaps, and coach teams through the process, so when the actual audit arrives, it’s not a scramble… it’s a showcase. ✅ Identify documentation gaps ✅ Stress-test your QMS ✅ Prepare your team for auditor interactions ✅ Reduce risk of non-conformities If you’ve got an audit on the horizon, now’s the time to act. Let’s talk about how mock audits can turn uncertainty into confidence. #MedicalDevices #QualityManagement #AuditReadiness #FDA #ISO13485 #MDR #MedTech #Compliance #MockAudit #LifeSciences #RegulatoryAffairs

15

3 Comments

I compared 2025 FDA Form 483s with ISO/AS9100 nonconformities. The overlap was brutal—and eye-opening. Two completely different frameworks. Two different auditor pools. One unavoidable conclusion: Your QMS is probably vulnerable in the same 5 places everyone else's is. Here's what rose to the top across hundreds of findings: #1: CAPA (by a mile) Investigations that don't investigate. Corrective actions that don't correct. Effectiveness checks that don't check. #2-5: The supporting cast → Design controls (incomplete DHFs, missing risk analysis) → Internal audits (calendar slippage, surface findings) → Management review (check-the-box meetings) → Training (no proof it worked) Notice the pattern? None of these are obscure. They're foundational. After 30 years building and fixing QMS, I'll tell you the truth: most quality failures aren't technical—they're cultural. Teams know what CAPA should be. They just don't have time/tools/buy-in to do it right. So they document what auditors want to see... until the auditor looks closer. If you're setting 2026 priorities, focus here: Make CAPA actually solve problems (not just close them) Turn audits into intelligence (not checkbox exercises) Build supplier controls that match your risk Prove training works (with evidence, not attendance sheets) Want the full FDA vs. ISO comparative breakdown? Comment "data" and I'll send it over. Because the best defense against findings? Fixing the basics before they become findings. #QualityManagement #RiskBasedThinking #ISO9001 #AS9100 #FDA #MedicalDevices

9

3 Comments

If your company cannot trace every component to its supplier in under 4 minutes, you are already at risk. 73% of medical device companies believe they are "audit-ready” until an FDA Form 483 or ISO nonconformity proves otherwise. At 1st M Consulting, we don't just prepare you for audits. We build structured, scalable quality systems aligned with FDA 21 CFR Part 820, ISO 13485:2016, ISO 9001, and ISO 14971 so your operations withstand real regulatory scrutiny without findings. We specialize in: • Transforming paper-based chaos into digital traceability systems (average implementation: 6-8 weeks) • Establishing full component-to-supplier traceability that auditors verify in real-time • Preparing companies for FDA and ISO audits with zero major nonconformities (94% client success rate) • Identifying critical risks 60-90 days before scheduled audits before they become Warning Letters Our clients avoid an average of $127,000 in audit remediation costs and 4-6 months of certification delays. Whether you are preparing for an upcoming audit or already facing compliance gaps that threaten your ISO certification, we provide hands-on implementation that turns regulatory uncertainty into documented control. With 35+ years of FDA and ISO audit experience across 200+ medical device manufacturers, we know exactly what inspectors scrutinize and how to fix it before they arrive. 📌 Schedule a 45-Minute Compliance Gap Assessment today.

2

Most device teams misunderstand design controls. They think it’s: ❌ FDA paperwork ❌ A pre-submission checkbox ❌ Something to clean up “before audit” But from the U.S. Food and Drug Administration’s perspective, design controls answer one question: “Can you prove this device was designed safely, intentionally, and for its intended use?” For medtech, biotech, neurotech, and SaMD, that means: • Clear design inputs (clinical + user needs) • Testable design outputs • Verification: did you build it right? • Validation: did you build the right thing? • Traceability inside a Design History File Weak design controls don’t just slow FDA clearance — they: • Delay SBIR Phase II • Kill diligence conversations • Force costly redesigns late in development I published a Design Controls 101 breakdown to help founders and operators understand what FDA actually expects — without regulatory jargon. Subscribe to my newsletter in bio!

1

When FDA reviewers or software standards like IEC 62304 refer to "system items", they’re talking about the conceptual building blocks that make up your software system—not necessarily the same thing as code modules or files. In FDA’s 2023 Guidance “Content of Premarket Submissions for Device Software Functions”, the system and software architecture diagram is described as a way to “present a roadmap” of the software’s major components (often called "modules" or "items"), their relationships, and data flows. The FDA leaves it up to the manufacturer to define what a “module” or “item” means in context, explicitly stating that “a module is not specifically meant to describe code-level software functions”. Similarly, IEC 62304 defines a software item as “any identifiable part of a computer program.” A software unit is simply a software item that is not further subdivided. This flexibility allows manufacturers to define decomposition based on the product’s architecture and risk, not on the folder structure of the codebase. In practice, *system items* (or software items) are the conceptual elements (e.g., algorithms, services, interfaces, databases, communication layers, UI components, etc.) that collectively realize your software’s intended use. Their main purpose in documentation is to help reviewers understand how your software achieves safety and effectiveness, not to document how every file or class is written. But Why Does This Matter? Teams often assume their architecture diagram must exactly match their repository layout. That assumption bloats submissions, slows reviews, and obscures what FDA actually cares about: how your software achieves its intended use safely and effectively, and how you’ve tested it. Read more about how your software diagrams can slow down your FDA Submission: https://hubs.li/Q03T8RWh0 #MedicalDeviceSoftware #FDASubmission #510k #IEC62304 #SoftwareAsAMedicalDevice #MedTechRegulatory #SaMD #FDAGuidance #MedicalDevices #DigitalHealth #RegulatoryAffairs #SoftwareDiagrams

14

Scrolling aimlessly won’t level up your MedTech regulatory knowledge. Following the right people will. If 2025 taught us anything, it’s this: regulatory careers don’t come with guaranteed stability. Layoffs happened, budgets stayed tight, and a lot of teams had to do more with less. 2026 will bring new challenges too. But it’s also a real opportunity to sharpen your skills, build authority in your niche, and stay competitive for what comes next. And the fastest lever you can pull today? Curate your LinkedIn feed. Not with random motivation posts or recycled hot takes. With experts who consistently share practical insights, updates, and frameworks you can actually use. Here are 8 MedTech regulatory voices worth following in 2025 (no particular order) - PART 1: Sean Smith ↳ Driving force behind a strong MedTech community. A real superconnector. Also runs webinars and workshops that are packed with value. Marina Daineko ↳ The person to follow for biocompatibility and toxicology. Weekly updates, clear explanations, and depth that’s hard to find elsewhere. EU MDR Compliance ↳ A seasoned MDR voice with practical guidance and some of the best regulatory infographics you’ll see. Bastian Krapinger-Ruether ↳ Focused on regulatory automation, PMS, AI, and quality. Great at breaking complex topics into clear takeaways. Georg Digel ↳ If CAPA is on your radar, follow Georg. Strong frameworks, real-world insights, and plenty of practical “how to” content. Karandeep Singh Badwal ↳ Deep knowledge across jurisdictions, plus an excellent MedTech podcast. Strong content on software and quality management. Ian Sealey ↳ One of the clearest voices on IEC 60601 and electrical safety. Also shares risk management perspectives and quiz-style learning posts. Monir El Azzouzi ↳ A broad and deep regulatory skill set, across posts, podcasts, and training. A great follow if you want a well-rounded view. It takes less than a minute to follow them. And your feed will change fast: less noise, more learning. There are more creators worth adding. I’ll share another list in my next post. What’s your regulatory goal for 2026? More confidence with MDR? Stronger PMS? Better CAPA? Getting deeper into standards? Something else? ⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡ MedTech regulatory challenges can be complex, but smart strategies, cutting-edge tools, and expert insights can make all the difference. I'm Tibor, passionate about leveraging AI to transform how regulatory processes are automated and managed. Let's connect and collaborate to streamline regulatory work for everyone! #automation #regulatoryaffairs #medicaldevices

152

48 Comments

🇪🇺Upcoming MDR Amendment (Chpt. I, Art. 1-4)🇪🇺 The foundational articles of Regulation (EU) 2017/745 are getting a major overhaul. If you're a manufacturer, regulatory professional, or QA/RA manager, here's your practical guide to the changes in Articles 1-4. 📋 ARTICLE 1: EXPANDED SCOPE What's Changing: Accessories to Annex XVI products (non-medical purpose devices like aesthetic lasers) are now regulated as medical devices Devices with integrated IVD components must comply with BOTH MDR and IVDR requirements Exclusions updated to align with new SoHO Regulation (EU) 2024/1938 Action Required: ✓ Identify if your Annex XVI product has accessories—they now need full technical documentation ✓ For combination products with IVD parts: conduct dual-compliance reviews ensuring the IVD component meets IVDR Annex I standards 📖 ARTICLE 2: UPDATED DEFINITIONS What's Changing: Nanomaterial definitions (points 18-21) DELETED from Article 2 NEW: "Well-Established Technology" (WET) definition—for simple, stable designs with long EU market history and no safety issues NEW: Regulatory sandbox framework for testing innovative products Enhanced "clinical data" definition with explicit PMS/PMCF references Action Required: ✓ Update your QMS glossaries immediately—remove old nanomaterial terms ✓ Review your portfolio against WET criteria for potential simplified compliance pathways ✓ Ensure Clinical Evaluation Plans reference the updated clinical data sources ⚖️ ARTICLE 3: WET IMPLEMENTATION What's Changing: Article 3 completely replaced. The Commission can now publish lists of devices that qualify (or don't qualify) as "Well-Established Technology" Action Required: ✓ Monitor upcoming Implementing Acts ✓ Update your Regulatory Strategy if your device gets WET designation 🔍 ARTICLES 4 & 4a: BORDERLINE PRODUCT CLARITY What's Changing: Mandatory consultation with EMA, ECHA, EFSA, and SoHO Coordination Board for borderline cases NEW formal pathway (Article 4a): manufacturers and Notified Bodies can request expert panel opinions on product regulatory status All coordination results must be publicly available Action Required: ✓ Use the formal request mechanism if your product sits between "device," "cosmetic," or "SoHO" ✓ Reference MDCG opinions and expert panel decisions in your technical documentation (Annex II, Section 1.1(e)) 📊 QUICK QMS/TECH DOC CHECKLIST: 🔧 Update your QMS procedures for Annex XVI accessory identification 📚 Add WET and Regulatory Sandbox terms 🩺 Update Clinical Evaluation Plans with new clinical data sources 🔬 Add IVDR compliance section for devices with integral IVD components ✅ Document WET qualification in device descriptions (if applicable) 💡 Bottom Line: Don't wait—start your gap analysis now. These changes affect technical documentation, QMS procedures, and regulatory strategy at the most fundamental level. #MedicalDevices #MDR #RegulatoryAffairs #QualityAssurance #MedTech #EURegulation #Compliance

24

CAPA is still the #1 issue cited in FDA 483s—but under QMSR, the expectation isn’t “open more CAPAs.” It’s make better, risk-based decisions—and be able to defend them. This is one of the most misunderstood shifts companies are walking into. #medicaldevice #compliance #FDA #qualitymanagement #medtech #biotech #regulatoryaffairs #qmsr

26

5 Comments

Most QMSR conversations still start in the wrong place, because they start with clause mapping. What the FDA made clear in the QMSR final rule—and even clearer in the preamble—is that this transition isn’t about renumbering procedures. It’s about whether risk is actually operating across your system, or just referenced when convenient. That distinction matters, believe you me, because under QMSR, “risk-based” isn’t limited to design files or hazard analyses. It’s expected to show up in supplier controls, CAPA decisions, management review inputs, and how systems inform each other over time. A static risk file won’t carry much weight anymore if the rest of the QMS doesn’t reflect it. This is also where the preamble quietly does a lot of work. You are reading the preamble, right? The preamble is where FDA explains how ISO 13485 concepts are expected to function inside U.S. inspections, where legacy expectations still apply, and why “ISO-certified” doesn’t automatically mean “inspection-ready” under the FD&C Act. Teams that are navigating this well didn't rush to update templates. They stepped back to really understand how FDA is interpreting system effectiveness, management responsibility, and risk integration. That kind of clarity tends to change how everything else gets built. If this transition feels heavier than you expected, there’s probably a reason—and it’s worth unpacking it while there’s still a little room to do it deliberately. 𝑭𝒆𝒃 2 𝒊𝒔 𝒐𝒏𝒍𝒚 𝒔𝒊𝒙 𝒅𝒂𝒚𝒔 𝒂𝒘𝒂𝒚. 𝑾𝒊𝒍𝒍 𝒚𝒐𝒖 𝒃𝒆 𝒓𝒆𝒂𝒅𝒚? #medicaldevice #compliance #FDA #qualitymanagement #medtech #biotech #regulatoryaffairs #startup #commercialization #riskmanagement #qmsr

37

6 Comments

How QA/RA teams can simplify internal audits. (Without sacrificing compliance.) Does this sound familiar: - Multiple audits every year? - Hours lost keeping track of changing requirements?   - Stress trying to prove compliance for each market? QMS requirements can feel endless.  (And every market adds their own unique ones.) It can be too complex for small MedTech orgs. But there's a smarter way to audit.  How I simplify compliance in 5 steps:  1. Combine all regulations into one internal audit.   2. Use AI to catch details often overlooked.   3. Focus on the 20% of issues causing 80% of problems.   4. Provide a report covering all relevant markets.   5. Deliver clear next steps to stay compliant.  One audit.  Full coverage.  Here’s the result:  - A single audit covering ISO 13485 and EU MDR. - (and US, Canada, Brazil, Australia, and Japan.)   - Less stress keeping up with regulatory changes.   - More time for innovation, less time spent on audits.  Compliance becomes manageable.  Audits become opportunities, not burdens.  --- If you’re juggling too many audits, I can help.  I’m offering AI-powered, human-driven audits to simplify compliance.  Spots this year are limited. DM me “Audit” today and let’s chat.  

6

For years, regulatory teams treated selecting their testing lab as a technical decision: choose a reputable lab + generate the data = submit the file. Unfortunately for foreign testing labs, that assumption has recently started to shift. FDA has issued warning letters to multiple foreign testing laboratories for GLP and data integrity deficiencies, including issues like reused animals in studies and lack of independent review of test results. At the same time, FDA shared that they will perform unannounced inspections of foreign manufacturers and facilities, part of a broader effort to re-evaluate how overseas production and testing are monitored. Not so bad, right? Well then came the WuXi situation. WuXi AppTec — previously considered a credible testing organization and used in many regulatory submissions — was drawn into scrutiny under the Biosecure Act, raising questions about whether certain foreign-generated data could be relied upon in regulatory submissions. The blowback was fierce, and Wuxi divested its U.S. laboratory operations after concerns about ownership, data access, and national security implications were raised. None of this is purely technical. It reflects a broader shift. Regulatory oversight now intersects with supply chain policy, geopolitical risk, and data sovereignty. Ten years ago, most regulatory strategies didn’t consider where safety testing was performed beyond basic accreditation. Today, the geography of your data may matter almost as much as the data itself. For companies building global regulatory strategies, that’s a signal worth paying attention to. #medicaldevice #compliance #FDA #qualitymanagement #medtech #biotech #regulatoryaffairs #510k #submissions #riskmanagement

16